$FLML (Flamel Technologies SA)

$FLML {{ '2015-10-05T16:33:49+0000' | timeago}} • Announcement

OTC consumer goods and pharmaceutical company $PRGO has entered into an exclusive licensing agreement with $FLML for its LiquiTime technology. $PRGO will use the LiquiTime platform to develop a portfolio of extended release suspension products intended for U.S. OTC market. Specific financial terms of the deal were not disclosed.

$LGND {{ '2018-01-11T17:54:53+0000' | timeago}} • Announcement

Pharma company $LGND has signed a license agreement with Glenmark Pharmaceuticals, allowing the latter to use the OmniAb platform for discovery of antibodies. For products incorporating OmniAb antibodies, Ligand will receive annual platform access payments and royalties, while the programs will be entirely funded by Glenmark.

$DEPO {{ '2018-01-10T17:44:57+0000' | timeago}} • Announcement

$DEPO announced the closing of its Commercialization Agreement for the US rights to commercialize both NUCYNTA Extended Release and NUCYNTA Immediate Release with Collegium Pharmaceutical Inc. In connection with the closing, $DEPO received an upfront $10MM cash payment from Collegium.

$LGND {{ '2018-01-03T14:25:12+0000' | timeago}} • Announcement

$LGND's partner HanAll Biopharma out-licensed antibody projects that were discovered by HanAll using $LGND’s OmniAb antibody discovery platform. The licensing events triggered $6MM of payments to $LGND. Including these payments, $LGND now anticipates total revenue for full year 2017 to be approx. $140MM with adjusted EPS to be $3.13-3.16.

$DEPO {{ '2017-12-04T22:44:23+0000' | timeago}} • Announcement

$DEPO signed a commercialization agreement with Collegium Pharmaceutical, Inc. For the first four years, $DEPO will receive a minimum royalty of $135MM per year. After year four, the royalty mechanism remains the same but without a minimum. The royalty rate will be adjusted post patent expiry, which is not expected until late 2025.

$DEPO {{ '2017-12-04T22:44:05+0000' | timeago}} • Announcement

$DEPO signed a commercialization agreement with Collegium Pharmaceutical, Inc., under which Collegium will commercialize NUCYNTA Extended Release and NUCYNTA Immediate Release. For this, $DEPO will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds. The deal is expected to close in early Jan. 2018.

$VIVO {{ '2017-10-19T17:11:02+0000' | timeago}} • Announcement

For FY18, $VIVO expects revenue of $207-212MM, representing growth of 3-6%.  The company sees GAAP EPS of $0.59-0.62 and non-GAAP EPS of $0.65-0.68. The company is increasing its focus on investments in R&D and sales and marketing. $VIVO expects the increased investments in these areas to drive higher revenue levels in FY18.

$VIVO {{ '2017-10-19T17:06:44+0000' | timeago}} • Announcement

$VIVO expects FY17 revenue of about $200.5MM, an increase of 2% compared to the prior year. The company predicts GAAP EPS of $0.50-0.51 and non-GAAP EPS of $0.66-0.67 for FY17. For 4Q17, $VIVO sees revenue of about $49.5MM, representing 5% growth compared to the prior year.

$DEPO {{ '2017-10-18T15:44:41+0000' | timeago}} • Announcement

$DEPO appointed Santosh Vetticaden as SVP, Chief Medical and Scientific Officer. Most recently, he held the position of Interim CEO of Insys Therapeutics Inc. Vetticaden currently serves on the board of Heluna Health (formerly Public Health Foundation Enterprises).

$MASI {{ '2017-10-16T21:02:15+0000' | timeago}} • Announcement

$MASI announced that the bankruptcy court in San Diego has issued final judgment holding that Sotera Wireless Employees misappropriated Masimo trade secrets. The misappropriation stems from two former Masimo employees, James Welch and David Hunt, copying thousands of confidential Masimo documents and using Masimo’s trade secrets to benefit Sotera.

$VIVO {{ '2017-10-10T16:19:48+0000' | timeago}} • Announcement

$VIVO has appointed John P. Kenny as CEO, effective October 9, 2017. He has also been appointed to $VIVO’s BoD effective October 9, 2017. Mr. Kenny comes to $VIVO from Siemens Healthcare. Concurrent with the hiring of Mr. Kenny, John A. Kraeutler, CEO & Chairman of the Board, steps down as CEO and takes the title of Executive Chairman.

$DEPO {{ '2017-10-10T13:44:58+0000' | timeago}} • Announcement

$DEPO said that as a result of the disruption to manufacturing operations in Puerto Rico due to Hurricane Maria, it is experiencing temporary delays in packaging and delivery of certain dosage strengths of NUCYNTA ER at the facility in Puerto Rico. Consequently, $DEPO expects its 4Q17 product revenue to be negatively impacted by less than $10MM.

$LGND {{ '2017-10-04T20:35:46+0000' | timeago}} • Announcement

$LGND agreed to buy Crystal Bioscience Inc. Crystal non-cash amortization expense estimates are expected to be determined in the near term. Including this acquisition, $LGND now sees 2017 total revenues to be at least $134MM, with potential for additional $9MM of contract payments, and adjusted EPS of about $2.93.

$LGND {{ '2017-10-04T20:34:48+0000' | timeago}} • Announcement

$LGND agreed to buy Crystal Bioscience Inc. This acquisition is projected to contribute up to $1MM of revenue and a similar level of operating expenses during 4Q17. For 2018, $LGND expects incremental Crystal revenues of at least $5MM and incremental EPS of at least $0.09.

$LGND {{ '2017-10-04T20:33:36+0000' | timeago}} • Announcement

$LGND agreed to buy Crystal Bioscience Inc. $LGND will pay Crystal shareholders $25MM in cash at closing, up to an additional $10.5MM of success-based milestones, and revenue sharing from existing licensees for a defined period.

$MASI {{ '2017-09-18T13:52:04+0000' | timeago}} • Announcement

$MASI announced FDA 510(k) clearance and full market release of Rad-97 Pulse CO-Oximeter, including configurations with integrated NomoLine capnography and noninvasive blood pressure measurement from SunTech Medical. Rad-97 offers Masimo noninvasive and continuous monitoring, through Measure-through Motion and Low Perfusion SET pulse oximetry.

$VIVO {{ '2017-09-05T18:48:26+0000' | timeago}} • Announcement

$VIVO's subsidiary, Meridian Life Science, Inc., announced the launch of TRU Block ULTRA. The advantage of TRU Block ULTRA is its active blocking technology across various assay types and its powerful assay interference blocking against human anti-mouse antibodies (HAMA), rheumatoid factor (RH), and heterophilic antibodies (HA).

$MASI {{ '2017-08-28T11:40:43+0000' | timeago}} • Announcement

$MASI said a study on the utility of its SpHb - a noninvasive hemoglobin measurement during oncosurgery on patients with high anticipated blood loss - has yielded positive results. It was found continuous SpHb monitoring can help in decision-making with regard to early blood transfusion, while allowing physician to focus on the haemoglobin trend.

$LGND {{ '2017-08-21T14:07:20+0000' | timeago}} • Announcement

$LGND appointed Nancy Ryan Gray to its BoD, effective Aug 21, 2017. Dr Gray currently serves as CEO of Gordon Research Conferences, a not-for-profit organization that arranges conferences in the biological, chemical, and physical sciences worldwide.

$LGND {{ '2017-08-18T14:40:01+0000' | timeago}} • Announcement

$LGND will receive a $2MM payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories. $LGND is also entitled to future milestones and royalties from this antibody.

$VIVO {{ '2017-08-09T18:24:11+0000' | timeago}} • Announcement

$VIVO has initiated clinical trials for a new illumigene CMV molecular amplification test. This assay is designed to specifically detect the congenital Cytomegalovirus (CMV) infection in newborns from saliva. Presently, there is no FDA-cleared test for CMV screening in newborns.

Recent Transcripts

ABEO (Abeona Therapeutics Inc.)
Monday, November 20 2017 - 3:00pm
BDSI (BioDelivery Sciences International, Inc.)
Thursday, November 9 2017 - 9:30pm
MGNX (MacroGenics, Inc.)
Wednesday, November 8 2017 - 9:30pm
LFVN (Lifevantage Corporation)
Wednesday, November 8 2017 - 9:30pm
MNKD (MannKind Corp.)
Tuesday, November 7 2017 - 10:00pm
DEPO (DepoMed Inc.)
Tuesday, November 7 2017 - 9:30pm
MZOR (Mazor Robotics Ltd.)
Tuesday, November 7 2017 - 1:30pm
CARA (Cara Therapeutics Inc.)
Thursday, November 2 2017 - 8:30pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
CSII (Cardiovascular Systems Inc.)
Wednesday, October 25 2017 - 8:45pm
LFVN (Lifevantage Corporation)
Thursday, September 7 2017 - 8:30pm
MEIP (MEI Pharma, Inc.)
Tuesday, September 5 2017 - 1:00pm
ABEO (Abeona Therapeutics Inc.)
Tuesday, August 22 2017 - 2:00pm
BDSI (BioDelivery Sciences International, Inc.)
Wednesday, August 9 2017 - 8:30pm
CRME (Cardiome Pharma Corp.)
Tuesday, August 8 2017 - 8:30pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
MNKD (MannKind Corp.)
Monday, August 7 2017 - 9:00pm
LGND (Ligand Pharmaceuticals Incorporated)
Monday, August 7 2017 - 8:30pm

AlphaGraphics you may like